Can we select NSCLC patients for immune checkpoint therapy?

Previous Page

Next Page

Page Background

First-Line IO: Does PD-L1 worth?

Reck - NEJM 2016 * Carbone - NEJM 2017

PD-L1 ≥50%

(22C3)

NIVOLUMAB

CHECKMATE 026

14.4 mo.

vs

13.2 mo.

HR= 1.02 (95%: 0.80 to 1.30)

PD-L1 ≥5%

(28-8)

Subgroup PD-L1 ≥50%,

HR=0.90 (95% CI, 0.63 to 1.29)

NEGATIVE FOR

PFS

-

OS immature

(coprimary

endpoint)

PD-L1 ≥25%

(SP263)

PEMBROLIZUMAB

KEYNOTE 024

DURVALUMAB

MYSTIC